Sandoz Eyes 2026 Aflibercept Launch With Regeneron Eylea Settlement

Litigation Deal Allows Enzeevu To Reach US Market In Q4 Next Year

Sandoz is looking to launch its Eylea biosimilar in 2026 (Shutterstock)

More from Biosimilars

More from Products